Compare Immunovant Inc. Common Stock (IMVT) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs ArcelorMittal SA — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while ArcelorMittal SA trades at $61.32 (market cap $47.06B). The key difference: ArcelorMittal SA is far larger — about 7.1× Immunovant Inc. Common Stock's market cap, and ArcelorMittal SA pays a 0.96% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and ArcelorMittal SA for 36 Days on average.
| IMVT | MT | |
|---|---|---|
Market Cap | $6.62B | $47.06B |
Volume | 1,131,364 | 1,545,197 |
Sector | Health | Basic Materials |
52-Week High | $44.96 | $78.74 |
52-Week Low | $17.03 | $36.91 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $5.72B | $56.63B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ArcelorMittal (MT) trades at $61.30, down 5.97% amid bearish technical signals and recent Ukraine plant impairment concerns. The stock shows mixed fundamentals with attractive valuation metrics (P/S 0.76, P/B 0.86) but declining revenue trends from $79.8B in 2022 to $61.4B in 2025. Recent Q2 2026 earnings missed expectations, though management expects stronger second-half performance supported by European demand recovery and strategic investments.
While analyst consensus remains bullish with a $74.33 price target (52% buy ratings), significant risks include ongoing Ukraine operations disruption, $1B impairment charge, and China demand weakness. The current price near support levels presents potential entry point for value investors, but requires careful monitoring of European recovery execution and geopolitical stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
